AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

NCT04468659 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

1400

Enrollment

INDUSTRY

Sponsor class

Conditions

Preclinical Alzheimer's Disease
Early Preclinical Alzheimer's Disease

Interventions

DRUG: Lecanemab
DRUG: Placebo

Sponsor

Eisai Inc.

Collaborators

Alzheimer's Clinical Trials Consortium
Biogen
National Institute on Aging (NIA)